• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Prepares Thousands of Dialysis Patients for Hurricane Milton

    10/8/24 1:38:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email

    TAMPA, Oct. 8, 2024  /PRNewswire/ -- DaVita Kidney Care, a leading provider of kidney care services, has activated its emergency response plan in preparation for Hurricane Milton's landfall in Florida. DaVita's emergency response plans focus on proactively dialyzing thousands of patients ahead of the storm in more than 150 centers.

    "Dialysis is a life-sustaining treatment, and our patients face unique challenges during weather emergencies like Hurricane Milton," said Priya Sequeira, senior vice president at DaVita. "Our top priorities are safety and continuity of care. We are working diligently to ensure our Florida centers, teammates and patients are prepared, and we will be ready to serve any patients in need once the storm passes."

    DaVita's local teammates have been providing patients with relevant medical information – including prescription, dietary instructions and fluid restrictions – should they need to dialyze at a different center. Approximately 50,000 Floridians currently receive dialysis treatment.

    "It's essential for patients on dialysis to have a comprehensive emergency plan in place, including backup plans for treatment and medications," said Dr. William Paxton, group medical director at DaVita. "Communication with caregivers and understanding local resources will greatly impact their ability to stay safe and manage their health through Hurricane Milton."

    DaVita is communicating evacuation information to patients and coordinating with other dialysis and health care providers to help ensure continuity of care for all patients. DaVita will help track where patients will be transferred and hold regularly scheduled check-ins with local teams to help coordinate the safety of those who are impacted.

    In the coming days, patients and their family members can visit https://newsroom.davita.com/2024-Hurricane-Milton-Updates for information on center closures during this emergency. Dialysis patients may call DaVita Guest Services at 1-800-400-8331 for help locating dialysis centers and scheduling treatment. If in need of urgent medical care, dial 9-1-1.

    Emergency Preparedness for People with Kidney Disease

    Kidney patients on dialysis should add several items to their emergency kit that will help meet their needs if an emergency happens. The kit should include the following:

    • Emergency phone numbers for doctors and dialysis centers, including alternate nearby dialysis centers
    • At least three days' worth of any medicines needed as well as a list of medicines and the dosage amount
    • For patients with diabetes, a week's worth of supplies (syringes, insulin, alcohol wipes, glucose monitoring strips)
    • At least three days' worth of emergency food

    Place these items in a container or bag that can be carried easily if evacuated or moved from home. Rotate the emergency kit's stock to make sure supplies are not past their expiration dates.

    For more information on emergency preparedness, visit https://www.davita.com/education/ckd-life/emergency-preparedness-for-people-with-kidney-disease.

    About DaVita Inc. 

    DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of June 30, 2024, DaVita served approximately 265,100 patients at 3,124 outpatient dialysis centers, of which 2,672 centers were located in the United States and 452 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

    Media Contact:

    Matthew Clyburn

    [email protected] 

    (860) 944-8653

    DaVita Logo (PRNewsfoto/DaVita)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-prepares-thousands-of-dialysis-patients-for-hurricane-milton-302270472.html

    SOURCE DaVita

    Get the next $DVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Ackerman Joel was granted 72,582 shares, increasing direct ownership by 49% to 221,019 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/12/26 4:05:56 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Chief Compliance Officer Hearty James O was granted 22,289 shares, increasing direct ownership by 85% to 48,587 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/12/26 4:06:07 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Chief Legal & Pub. Affairs Off Waters Kathleen Alyce was granted 56,159 shares, increasing direct ownership by 57% to 155,277 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/12/26 4:05:49 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    SEC Filings

    View All

    SEC Form 10-K filed by DaVita Inc.

    10-K - DAVITA INC. (0000927066) (Filer)

    2/11/26 4:06:39 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    2/2/26 4:07:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    11/25/25 5:01:10 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference

    DENVER, Feb. 24, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026 at 11:50 am EST.To view the live webcast, visit the TD Cowen page here and create a free registration.About DaVita Inc.DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita c

    2/24/26 2:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Elara Caring Secures New Strategic Investment from Ares and DaVita

    Partnership will accelerate Elara's growth and evolution as home health care leader; expand access to high-acuity care for complex diseases through new offerings Elara Caring (Elara), a leading national provider of skilled home health, hospice, behavioral health, and personal care services, today announced that it has entered into an agreement for a strategic investment from Ares' Private Equity Group (Ares) and DaVita. The investment is intended to expand access to personalized, clinically advanced care at home for patients with complex and acute needs. Elara will continue to operate as a wholly independent company led by CEO Ananth Mohan and the current management team. Following the cl

    2/2/26 3:00:00 PM ET
    $ARES
    $DVA
    Investment Managers
    Finance
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on DaVita with a new price target

    Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

    3/6/24 8:09:27 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita upgraded by UBS with a new price target

    UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

    8/7/23 7:20:56 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

    11/1/22 9:18:39 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    9/13/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    5/13/24 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call

    DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, February 2, 2026Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen

    1/21/26 10:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 3rd Quarter 2025 Results

    DENVER, Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance," said Javier Rodriguez, CEO of DaVita. "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving the lives of our patients and supporting our dedicated teammates and physician partners." Financial and operating highlights for the quarter ended September 30, 2025: Consolidated revenues were $3.420 billion.Operating income was $506 million and adjusted operating

    10/29/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/9/22 3:43:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

    SC 13D/A - DAVITA INC. (0000927066) (Subject)

    8/4/21 4:02:59 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care